<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247233</url>
  </required_header>
  <id_info>
    <org_study_id>RTS02-SHARE</org_study_id>
    <secondary_id>2010-A00243-36</secondary_id>
    <secondary_id>UC-0140/1001</secondary_id>
    <secondary_id>RTS02 / SHARE</secondary_id>
    <nct_id>NCT01247233</nct_id>
  </id_info>
  <brief_title>Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer</brief_title>
  <acronym>SHARE</acronym>
  <official_title>Phase III Multicentric Trial Comparing Accelerated Partial Breast Irradiation (APBI) Versus Standard or Hypofractionated Whole Breast Irradiation in Low Risk of Local Recurrence of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment for localized breast cancer is based on conservative surgery (when
      possible) followed by radiation therapy (RT) delivered to the whole breast. The recommended
      total RT dose is 45 to 50 Gy delivered in 4.5 to 5 weeks followed by a 10 to 16 Gy boost to
      the tumor bed for 1 to 1.5 weeks. The rationale for the development of APBI was based on the
      difficulty for many patients to reach RT centers to receive standard whole breast irradiation
      (WBI) after conservative surgery. APBI offers decreased overall treatment time and several
      theoretical advantages over WBI, including a decrease in dose delivered to uninvolved
      portions of the breast and adjacent organs. If equivalence between the two treatments can be
      shown, then APBI will be considered as a historic evolution in breast cancer management.

      In this phase III trial, designed in postmenopausal women &gt; 50 years of age, the objective is
      to compare the effectiveness and safety of APBI compared with whole breast irradiation. This
      study is also designed to ensure high quality criteria for surgery, pathology and RT
      techniques in the 3 arms and will allow to provide data on economics and costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following breast conservative surgery, patients will be stratified according to the following
      prognostic factors using a minimisation technique: age (&lt;70 vs ≥70), HER2 status (HER2+ vs
      HER2-), hormonal receptor status (RH+ vs RH-) and lymph node invasion (pN0 vs pN0i+).

      Patients will be allocated to receive either standard treatment, hypofractionated treatment
      or APBI.

      Radiation therapy should be started between 4 and 12 weeks after the last surgery.

      Patients treated with standard whole breast irradiation will receive a total dose of 50 Gy in
      25 fractions, 2 Gy per day, 5 days a week. The boost of 16 Gy will be delivered in 8
      fractions for all patients after completion of the 50 Gy, without interruption. All patients
      will receive one fraction per day, 5 fractions a week.

      Patients treated with hypofractionated irradiation will receive a total dose of either 40 Gy
      (in 15 fractions, 2.66 Gy per day) or 42.5 Gy (in 16 fractions, 2.65 Gy per day)5 days a
      week.

      Patients treated with APBI will receive a total dose of 40 Gy in 10 fractions, delivered
      twice a day over a time period of 5-7 days. Each daily dose must be separated by 6 hours.

      Patients will be followed at 3 and 6 month after the last dose of irradiation, at 12 months
      after the date of last surgery and then on a yearly basis during 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of local recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate and compare the rate of local recurrence between the experimental and control arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral breast recurrence-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate Ipsilateral breast recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodal regional recurrence-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate nodal regional recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate distant recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate disease-specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate the overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities: Measurement of the rate and type of toxicity (acute and late toxic effects)</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate rates and type of acute and late toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic: comparison of the cosmetic result (according to both the physician and the patient)</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate Cosmetic results (Patient and Physician evaluations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Satisfaction</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate the patient quality of life and patient satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic study</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the cost of APBI compared with Standard and Hypofractionated irradiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1006</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lumpectomy</condition>
  <arm_group>
    <arm_group_label>Standard or Hypofractionated radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whole breast RT, 50Gy + &quot;boost&quot; 16Gy. Whole breast hypofractionated RT without boost, either 40Gy or 42,5Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Partial Breast Irradiation (APBI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed .</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Breast Irradiation + Boost or Hypofractionated irradiation</intervention_name>
    <description>Whole Breast Irradiation 50Gy + Boost 16 Gy or Whole breast, either 40Gy in 15 fractions in 3 weeks or 42,5Gy in 16 fractions in 3 weeks</description>
    <arm_group_label>Standard or Hypofractionated radiotherapy</arm_group_label>
    <other_name>Standard radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated partial breast irradiation</intervention_name>
    <description>Tumor bed 40Gy in 10 fractions, 2 fractions of 4Gy per day in 5 to 7 days.</description>
    <arm_group_label>Accelerated Partial Breast Irradiation (APBI)</arm_group_label>
    <other_name>APBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥ 50 years

          -  Menopausal status confirmed

          -  Pathology confirmation of invasive carcinoma (all types)

          -  Complete tumor removal and conservative surgery

          -  Pathologic tumor size of invasive carcinoma ≤ 2cm (including the in situ component)
             pT1

          -  All histopathologic grades

          -  Clear lateral margins for the invasive and in situ disease (&gt; 2mm)

          -  pN0 or pN(i+)

          -  No metastasis

          -  Radiotherapy should be started more than 4 weeks and less than 12 weeks after last
             surgery

          -  Surgical clips (4 to 5 clips in the tumor bed)

          -  No prior breast or mediastinal radiotherapy

          -  ECOG 0-1

          -  Information to the patient and signed informed consent

        Exclusion Criteria:

          -  Multifocal invasive ductal carcinoma defined as the presence of at least two distinct
             tumors that are separated by normal tissue or when the distance between the two
             lesions does not permit conservative surgery

          -  Bilateral breast cancer

          -  No or less than 4 surgical clips in the tumor bed

          -  Nodal involvement : pN1 (including micrometastasis, mi+), pN2, pN3

          -  Metastatic disease

          -  internal mammary node involvement or supraclavicular lymph node involvement

          -  Indication of chemotherapy or trastuzumab

          -  Involved or close lateral margins for the invasive and /or in situ components (&lt; 2mm)
             AND impossibility to re-operate or impossible to perform another conservative surgery

          -  Patients with known BRCA1 or BRCA2 mutations

          -  Previous mammoplasty

          -  Previous homolateral breast and/or mediastinal irradiation

          -  Previous invasive cancer (except basocellular epithelioma or in situ carcinoma of the
             cervix)

          -  No geographical, social or psychologic reasons that would prevent study follow
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazid Belkacemi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital AP-HP, Créteil, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Lartigau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oscar Lambret Hospital, Lille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Céline Bourgier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Montpellier, Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de traitement des Hautes energie - Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Brive</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Chambery</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Montélimar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly sur Seine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Haute Energie</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Stauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Marie Curie</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>Accelerated Partial Breast Irradiation</keyword>
  <keyword>invasive cancer</keyword>
  <keyword>Hypofractionated Irradiation</keyword>
  <keyword>Lumpectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

